Uterine Fibroid Market Research Report - U.S. Forecast to 2022

Uterine Fibroid Market Research Report - U.S. Forecast to 2022

ID: MRFR/HC/1766-CRR | March, 2017 | Region: Global | 47 pages | Cooked Research Reports

U.S. Uterine Fibroid Market Information by Type (Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others), by Diagnosis (Medical Resonance Imaging (MRI) scanners, Computed Tomography (CT), Ultrasounds and others) and Treatment (Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy) - Forecast to 2022


Market Synopsis of U.S.  Uterine Fibroid Market:


Market Scenario:
Uterine Fibroids are the abnormal growth that gets developed inside or on the wall of a woman’s uterus. These are also known as leiomyoma or myomas. These are noncancerous growths that cause symptoms such as heavy bleeding between or during the menstrual cycle, pain in pelvis or lower back, increased menstrual cramping, swelling enlargement of the abdomen. Increasing prevalence due to heredity and rising number of treatments to cure this disease has fuelled the growth of this market. 
The U.S. Market for Uterine Fibroids is expected to reach USD 39,993.2 million by the end of the forecasted period and is expected to grow at a CAGR of 3.24%.


Study Objectives U.S. Uterine Fibroid Market:



  • To provide detailed analysis of the market structure along with forecast for the next 5 years of the various segments and sub-segments of the U.S. Uterine Fibroid Market

  • To provide insights about factors affecting the market growth

  • To analyze the market based on various factors - price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to four main geographies and their countries- Americas, Europe, Asia-Pacific, and Middle East & Africa.

  • To provide country level analysis of the market with respect to the current market size, volume, average selling price and future prospective

  • To provide overview of key players and their strategic profiling in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments U.S.


U.S. Uterine Fibroids Market, By Type, 2015 & 2022 (USD Million):
U.S. Uterine Fibroids Market Image




Key Finding



  • The U.S. Uterine Fibroid market and is expected to reach USD 39,993.2 million by 2022.

  • By Type, Intramural Fibroids holds the largest market share of U.S. uterine fibroid market and is expected to reach USD 14,972.5 million by 2022.

  • By Treatment, hysterectomy holds the largest market share of U.S. uterine fibroid market and is expected to reach USD 8,042.3 million by 2022.


Key Players for U.S.  Uterine Fibroid Market:
Some of the key players in this market are: AstraZeneca (England), Cook Medical Inc. (US), Boston Scientific Corporation (US), GE Healthcare (U.K.), AbbVie Inc. (U.S.), Hologic (U.S.), and others.


Segments:
U.S. Uterine Fibroid Market has been segmented on the basis of type which comprises of Subserosal Fibroids, Intramural Fibroids, Submucosal Fibroids and others. On the basis of diagnosis the market is segmented into Medical Resonance Imaging (MRI) scanners, Computed tomography (CT), Ultrasounds and others. On the basis of treatment the market is segmented into Uterine Fibroid Embolization, Magnetic Resonance Guided Focused Ultrasound, Myolysis, Endometrial Ablation, Hysterectomy and Myomectomy.


Regional Analysis of U.S. Uterine Fibroid Market:
The U.S. market for uterine fibroids is growing steadily. The market for uterine fibroids is growing with the CAGR of 3.24% during the forecast period from 2016-2022. California, Texas, Florida, New York are some of the states which are estimated to have highest prevalence of uterine fibroids.                         


The report for U.S. Uterine Fibroid Market of Market Research Future comprises extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.

Intended Audience



  • Uterine Fibroid Devices and Drug Manufacturers

  • Uterine Fibroid Devices and Drug Suppliers

  • Private Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Medical Research Laboratories


 

License

Single User Enterprise User (Buy Premium Reports Chapterwise)
Currency

TABLE OF CONTENTS

1.1.1 Prevalence of the Uterine Fibroids in U.S. 8

2.1 Research Objective 10


2.2 Assumptions & Limitations 10


2.2.1 Assumptions 10


2.2.2 Limitations 10


2.3 Market Structure 11

3.1 Primary Research 13


3.2 Secondary Research 13

4.1 Introduction 15


4.2 U.S. Uterine Fibroid Market, By Type 17


4.3 U.S. Uterine Fibroid Market, By Diagnosis 19


4.4 U.S. Uterine Fibroid Market, By Treatment 21

5.1 AstraZeneca 29


5.1.1 Company Overview 29


5.1.2 Product overview 29


5.1.3 Financial Overview 30


5.1.4 Key Development 31


5.1.5 SWOT Analysis 32


5.2 Cook Medical Inc. 33


5.2.1 Overview 33


5.2.2 Product Overview 33


5.2.3 Financials 33


5.2.4 Key Developments 33


5.2.5 SWOT Analysis 34


5.3 Boston Scientific Corporation 35


5.3.1 Company Overview 35


5.3.2 Product/Business Segment Overview 35


5.3.3 Financial Overview 35


5.3.4 Key Development 36


5.3.1 SWOT Analysis 37


5.4 GE Healthcare 38


5.4.1 Company Overview 38


5.4.2 Product/Business Segment Overview 38


5.4.3 Financial Overview 38


5.4.4 Key Development 40


5.4.5 SWOT Analysis 40


5.5 AbbVie Inc. 41


5.5.1 Company Overview 41


5.5.2 Product/Business Segment Overview 41


5.5.3 Financial Overview 41


5.5.4 Key Development 43


5.5.5 SWOT Analysis 43


5.6 Hologic, Inc. 44


5.6.1 Company Overview 44


5.6.2 Product/Business Segment Overview 44


5.6.3 Financial Overview 44


5.6.4 Key Development 46


5.6.5 SWOT Analysis 46



TABLE 1 U.S. UTERINE FIBROID MARKET, BY TYPE, 2013-2022 (USD MILLION) 18

TABLE 2 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2013-2022 (USD MILLION) 20

TABLE 3 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2013-2022 (USD MILLION) 23

TABLE 4 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2013-2022 (USD MILLION) 24

TABLE 5 PIPELINE PRODUCTS FOR UTERINE FIBROIDS 27

TABLE 6 ASTRAZENECA: KEY DEVELOPMENT 31

TABLE 7 BOSTON SCIENTIFIC CORPORATION: KEY DEVELOPMENT 36

TABLE 8 GE HEALTHCARE: KEY DEVELOPMENT 40

TABLE 9 ABBVIE INC.: KEY DEVELOPMENT 43

TABLE 10 HOLOGIC INC.: KEY DEVELOPMENT 46

FIGURE 1 COMPARISON BETWEEN DIAGNOSIS & TREATMENT MARKET, 2013-2022 (USD MILLION) 9

FIGURE 2 U.S. UTERINE FIBROID MARKET: MARKET STRUCTURE 11

FIGURE 3 RESEARCH PROCESS 12

FIGURE 4 U.S. UTERINE FIBROID MARKET, BY TYPE, 2015 & 2022 (USD MILLION) 18

FIGURE 5 U.S. UTERINE FIBROID MARKET, BY DIAGNOSIS, 2015 & 2022 (USD MILLION) 20

FIGURE 6 TREATMENTS FOR UTERINE FIBROIDS 22

FIGURE 7 U.S. UTERINE FIBROID MARKET, BY TREATMENT, 2013-2022 (USD MILLION) 23

FIGURE 8 U.S. UTERINE FIBROID MARKET, BY TREATMENT TYPE, 2015 & 2022 (USD MILLION) 24

FIGURE 9 PHARMACOTHERAPY TREATMENT FORECAST, 2015-2022 26

FIGURE 10 ASTRAZENECA: RECENT FINANCIAL 30

FIGURE 11 ASTRAZENECA: GEOGRAPHICAL MIX 30

FIGURE 12 ASTRAZENECA: OPERATING SEGMENTS 31

FIGURE 13 ASTRAZENECA: SWOT ANALYSIS 32

FIGURE 14 BOSTON SCIENTIFIC CORPORATION: RECENT FINANCIAL 35

FIGURE 15 BOSTON SCIENTIFIC CORPORATION: RECENT FINANCIAL 36

FIGURE 16 BOSTON SCIENTIFIC CORPORATION: SWOT ANALYSIS 37

FIGURE 17 GE HEALTHCARE: RECENT FINANCIAL 38

FIGURE 18 GE HEALTHCARE: GEOGRAPHICAL MIX 39

FIGURE 19 GE HEALTHCARE: OPERATING SEGMENTS 39

FIGURE 20 GE HEALTHCARE: SWOT ANALYSIS 40

FIGURE 21 ABBVIE INC.: RECENT FINANCIAL 41

FIGURE 22 ABBVIE INC.: GEOGRAPHICAL MIX 42

FIGURE 23 ABBVIE INC: OPERATING SEGMENTS 42

FIGURE 24 ABBVIE INC.: SWOT ANALYSIS 43

FIGURE 25 HOLOGIC INC.: RECENT FINANCIAL 44

FIGURE 26 HOLOGIC INC: GEOGRAPHICAL MIX 45

FIGURE 27 HOLOGIC INC: OPERATING SEGMENTS 45

FIGURE 28 HOLOGIC INC.: SWOT ANALYSIS 46